Abstract
This article reports Taiwan's efforts to replicate remdesivir to prepare for combating COVID-19. There were two state-funded institutions and two private pharmaceutical companies working on remdesivir synthesis. They all claimed to successfully complete remdesivir of a high purity. But, since Gilead Sciences, Inc. has patented remdesivir in Taiwan, the Taiwan Government needs to initiate compulsory licensing under the Patent Act to start large-scale manufacturing of remdesivir within its territory.
Get full access to this article
View all access options for this article.